Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

ALMACAVIR (ENTECAVIR) FILM COATED TABLETS 0.5MG [SIN16612P]

Active ingredients: ENTECAVIR MONOHYDRATE EQV ENTECAVIR

View product's general information
Last updated 16 September 2026

Product Info

ALMACAVIR (ENTECAVIR) FILM COATED TABLETS 0.5MG

[SIN16612P]

Product information

Active Ingredient and Strength

ENTECAVIR MONOHYDRATE EQV ENTECAVIR - 0.5 MG

Dosage Form

TABLET, FILM COATED

Manufacturer and Country

GENUONE SCIENCES INC. - KOREA, REPUBLIC OF

Registration Number

SIN16612P

Licence Holder

ALMA-A PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

J05AF10

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

[INDICATIONS AND USAGE]

Almacavir® is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
The following points should be considered when initiating therapy with Almacavir®:
This indication is based on histologic, virologic, biochemical, and serologic responses in nucleoside-treatment-naïve and lamivudine-resistant adult subjects with HBeAg-positive or HBeAg-negative chronic HBV infection with compensated liver disease.

  • Virologic, biochemical, serologic, and safety data are available from a controlled study in adult subjects with chronic HBV infection and decompensated liver disease.
    Virologic, biochemical, serologic, and safety data are available for a limited number of adult subjects with HIV/HBV co-infection who have received prior lamivudine therapy.

Dosing

[DOSAGE AND ADMINISTRATION]

Recommended Dosage

Compensated Liver Disease
The recommended dose of Entecavir for chronic hepatitis B virus infection in nucleoside-treatment-naïve adults and adolescents 16 years of age and older is 0.5 mg once daily, with or without food. The recommended dose of Entecavir in adults and adolescents (≥ 16 years of age) with a history of hepatitis B viremia while receiving lamivudine or known lamivudine resistance mutations is 1 mg once daily, which must be taken on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal).

Decompensated Liver Disease
The recommended dose of Entecavir for chronic hepatitis B virus infection in adults with decompensated liver disease is 1 mg once daily, which must be taken on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal).

Renal Impairment
In subjects with renal impairment, the apparent oral clearance of Entecavir decreased as creatinine clearance decreased. Dosage adjustment is recommended for patients with creatinine clearance less than 50 mL/min, including patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), as shown in Table 1. The once-daily dosing regimens are preferred.

Almacavir Dosage Table 1



Hepatic Impairment
No dosage adjustment is necessary for patients with hepatic impairment.

Duration of Therapy
The optimal duration of treatment with Entecavir for patients with chronic hepatitis B virus infection and the relationship between treatment and long-term outcomes such as cirrhosis and hepatocellular carcinoma are unknown.

Contraindications

[CONTRAINDICATIONS]

Entecavir is contraindicated in patients with previously demonstrated hypersensitivity to entecavir or any component of the product.